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1. INTRODUCTION 
 
1.1 Neurodegeneration caused by mitochondrial dysfunction 
Neurodegenerative diseases are generally considered as a group of disorders that 
seriously and progressively impair the functions of the nervous system through selective 
neuronal vulnerability of specific brain regions. Neurodegeneration is a common theme of 
many severe diseases, such as Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, 
Amyotrophic Lateral Sclerosis (ALS), head trauma, epilepsy and stroke. These disorders are 
devastating for the patient and their families. Furthermore, the annual cost of medical care at 
present exceeds several hundred billion dollars in the United States alone, and current 
treatments are inadequate. Adding to the urgency of the problem is the fact that the incidence 
of these neurodegenerative disorders is increasing rapidly as population demographics 
change (Kondo 1996). An element of mitochondriopathy has been implicated in most of 
these neurodegenerative disorders, and is one of the leading areas of research (Lin and Beal, 
2006). Among the common neurodegenerative diseases, however, are rare and orphaned 
diseases which are neglected from therapeutic research, and form a group of diseases 
subjected to slow and crawling progress. Leber’s Hereditary Optic Neuropathy (LHON) is a 
prime example of such a neurodegenerative disease which is linked to mitochondrial DNA 
point mutation (Harding and Sweeny, 1994). 
 
Mitochondria are cellular organelles encircled by cardiolipin rich inner membrane 
(IMM) and surrounded by an outer membrane (OMM). Series of enzyme complexes are 
present in the IMM known collectively to constitute the electron transport chain (ETC), 
which is the most effective way for the cell to synthesize ATP by phosphorylation of ADP. 
The ETC consists of five complexes (Figure 1): complex I or NADH:ubiquinone 
oxidoreductase contains 41 subunits, complex II (succinate dehydrogenase) contains 5 
subunits, cytochrome c reductase or complex III is made up of 11 subunits, complex IV 
(cytochrome c oxidase) consists of 13 subunits, and complex V (ATP synthase) is composed 
of 14 subunits. Briefly, the complex I accepts electron from the major donor NADH and 
couples it with the expulsion of protons from the matrix to the inter-mitochondrial membrane 
space. The electron moves successive to complex III and complex IV to repeat the expulsion 
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of protons from both complexes. FADH2, which is also a reducing product of the Kreb’s 
cycle donates its electron to complex II, which again successively passes the electron to 
complex III and IV. The expelled protons create an electrochemical gradient, which is 
utilized by complex V to couple the energy of travelling H
+
 ions (towards the mitochondrial 
matrix) to oxidative phosphorylation, and ATP production. ETC is also the most important 
location of free radical generation due to the escape of electrons from the chain during 
oxidative phosphorylation (mostly at complex I and complex III). This is most certainly 
obvious with mitochondria harboring defective ETC. 
 
Figure 1: A diagrammatic representation of the electron transport chain (ETC). Complex I-V are labeled with their 
respective roman numerals, CoQ=coenzyme Q, CytC=cytochrome C, IMM=inner mitochondrial membrane; 
mtDNA=mitochondrial DNA, H
+
 represents the proton flow and e
-
 shows the movement of the electron 
through the complexes. The resulting LHON mutation is indicated in complex I. 
LHON mutation 
Mitochondrion 
mtDNA 
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Mitochondria, besides playing the role of energy house of the cell, are unique in the 
sense that they are the only organelles that contain its own copies of distinct circular DNA 
within the matrix space. The mitochondrial DNA (mtDNA) is maternally inherited from the 
ova during fertilization. This circular DNA, which is present at about 100-100000 copies per 
cell constitutes of 16,569 base pairs with a total of 37 genes, 13 of which are for the 
structural proteins of the electron transport chain (7 complex I subunits, 1 complex III 
subunit, 3 complex IV subunits, and 2 complex V subunits). The remaining 24 genes encode 
for 22 tRNAs and 2 ribosomal RNA molecules, which are necessary for the synthesis of the 
structural proteins (Weisner et al., 1992).  
 
The rules of mitochondrial genetics differ from those of nuclear DNA (nDNA) in 
several ways. Firstly, the mtDNA is more prone to mutation as it lies in close proximity of 
the major ROS producing unit causing oxidative damage, and secondly, it lacks histones that 
might provide protection. Also a popular belief that the mitochondria do not have adequate 
repair mechanisms, a view that is no longer valid (Weissman et al., 2007; Bohr and Anson, 
1999), has been perceived to contribute to the higher susceptibility of mtDNA damage and to 
play a role in ageing (Weisner et al., 2006). The circular mtDNA can exist in heteroplasmic 
forms, i.e. the wild type can coexist with the mutated copies. The phenotypic consequence of 
the mutation depends on the load of mutated DNA compared to the wild type. If this load 
exerts a substantial burden then the functional consequence become evident. The 
heteroplasmic threshold may vary among cells, with the most aerobically active cells being 
most likely to express the mutation, and therefore to be most affected. Due to the expression 
of the mutation when the ETC failure or oxidative stress is severe, membrane depolarization 
occurs. This is most evident in neurons undergoing NMDA toxicity, in which mitochondria 
accumulate cytosolic calcium and undergo the phenomenon of mitochondrial permeability 
transition pore (mtPTP) formation preceding apoptosis (Andrabi et al., 2004). 
 
DiMauro enlisted a few mitochondrial diseases as a consequence of mtDNA and 
nDNA mutation. The listing of diseases due to mtDNA mutation included some of the 
relatively well known syndromes like LHON, mitochondrial encephalopathy, lactic acidosis, 
stroke like episodes syndrome (MELAS), and myoclonic epilepsy with ragged-red fibre 
syndrome (MERRF) along with Person’s syndrome and various myopathies due to defective 
complex I, complex II, and complex III (DiMauro 2004). LHON is among the most 
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important examples of neurodegenerative diseases caused by mtDNA mutation. Other 
neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, Huntington’s 
disease and ALS carry an element of dysfunctional mitochondria (Petrozzi et al., 2007), but it 
is not entirely clear if this is a primary mitochondrial defect. Recent advances in molecular 
genetics suggest mitochondrial dysfunction in an ever increasing list of degenerative 
disorders (DiMauro and Davidzon, 2005). 
 
 1.2 LOHN disorder: a mitochondriopathy 
LHON disorder has been recognized since eighteenth century, when it was mistaken 
for an infective disease passed on to the child by the carrier mothers. Theodor Leber was the 
first who described the disorder as a familial neuropathological disease in 1871. Nearly a 
century later, a novel mode of maternal cytoplasmic inheritance was suggested in the disease 
(Erickson 1972). Recent advances in research, however, have deciphered the genetic basis of 
the disease and its link to mtDNA (Brown et al., 1992). A point mutation in the mtDNA 
affecting the complex I of the respiratory chain leading to high oxidative stress has been 
claimed responsible for the disorder (Qi et al., 2007a; Battisti et al., 2004; Johns and Colby 
2002). LHON is a retinal ganglionic neurodegenerative disorder characterized by an acute or 
G13708A 
G3460A 
T4216C 
T14484A 
G15257A 
ND4 
ND1 
ND5 
ND6 
ND2 
ND3 
 
G11778A 
 
Mitochondria 
mtDNA 
Figure 2: Mitochondrial genome (mtDNA). The seven complex I subunits along with primary LHON 
mutation (Green background) are presented.  
ND4L 
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sub-acute, bilateral central vision loss due to degeneration of retinal ganglion cells and the 
optic nerve. It is occasionally associated with a progressive movement disorder (Novotny 
et al., 1986; Shoffner et al., 1995). The disorder constitutes to be the commonest cause of 
blindness in otherwise healthy males. The visual loss is described as fogging or blurring in 
one eye at first, and eventually in the other with an interval of a few days to months. In most 
patients the nerve fibre layer around the optic disc is swollen with presence of tortuous 
retinal arterioles and telangiectasies in the peripapillary small vessels. The age of onset of 
symptoms tends to be earlier in males (16-30 years) as compared to females (22-63 years), 
but the clinical symptoms are not markedly different among the sexes (Harding and Sweeney 
1994).  
 
The primary cause of LHON disorder is a maternally inherited mtDNA point mutation. 
Until now, only a handful of definitively proven pathogenic mutations (so called primary 
LHON mutations) have been established (Figure 2), all of which lead to amino acid 
exchanges in some subunits of the NADH:ubiquinone-oxidoreductase (complex I) of the 
respiratory chain. Only three of these mutations located at base pairs 3460, 11778, and 14484 
in the mitochondrial genome have been observed most frequently in more than a few families 
worldwide and contribute to majority of LHON cases (Figure 2). The majority of mutations 
corresponding to 3460, 11778, and 14484 base pairs of the mitochondrial DNA affect the 
ND1 (NADH dehydrogenase 1), ND4, and ND6 subunits of the ETC complex I, respectively. 
There are so far also at least 37 LHON related point mutations of the mtDNA which have 
been reported (Harding and Sweeney 1994). Wallace et al. previously suggested that the 
mutation at base pair 11778 was homoplasmic (Wallace et al., 1988), which was then later 
rectified by studies in the UK suggesting it can be heteroplasmic (Holt et al., 1989). 
 
1.2.1 Epidemiology of LHON 
 
LHON is by far the most frequent disorder of mitochondrial genetic diseases (Carelli 
et al., 2004b). It occurs with an estimated prevalence of 1 in 25000 people in North East 
England. About 2 % of registered blinds in Australia suffer from LHON (Man et al., 2003). 
The prevalence of LHON in Finland is 1:50000, and one in 9000 Finns is a carrier of one of 
the three LHON primary mutations (Puomila et al., 2007). The 11778 mutation is responsible 
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for 31-89% of LHON pedigrees in Europe, North America, and Australia and 90% of LHON 
pedigrees in Japan (Kerrison and Newman, 1997). LHON is also characterized by a marked 
gender bias, with males more likely to become affected than females and a slight increase in 
the age of onset in females (Macmillan et al., 1998; Harding et al., 1995; Newman et al,. 
1991). Affected females, however, do not have more affected children than unaffected 
females (Macmillan et al., 1998). There has also been observed a difference in higher 
incidence of visual recovery among patients with the 14484 mutation compared to the other 
two most prominent mutations (Johns et al., 1993). Finally, up to 60% of LHON carriers will 
give a reliable history of other maternal relatives being affected. The remainder most likely 
represents cases where family history is difficult to trace back, given that de novo mutation is 
rare in LHON. 
 
1.2.2 Pathological pathways in LHON indicate mitochondrial dysfunction 
 
In the 1970s LHON disorder was thought to be an infectious disease transmitted by a 
virus infecting the child in the uterus of carrier mothers. With the progression of the field of 
mitochondrial medicine, however, became more evident that the disorder is due to the 
presence of mtDNA mutation as the primary cause (Swerdlow 2002). Singh and colleagues 
discovered the presence of the G to A point mutation at the base pair 11778 in the mtDNA in 
the LHON kindred (Singh et al., 1989). The loss of vision is generally painless, although it 
can occur with painful eye movements in some patients (Mroczek-Tonska et al., 2003). 
 
Among the mutation harboring population only 50% males and only 10% females 
actually develop the optic neuropathy. This incomplete penetrance of the mutation suggests 
additional genetic and environmental factors modulating the phenotypic expression of LHON 
symptoms (Man et al., 2002). As shown in cybrid (an abbreviation for cytoplasmic hybrid) 
cell cultures, the amino acid sequence changes of the mitochondrial complex I affect its 
functioning and lead to a decrease in mitochondrial ATP-synthesis (Baracca et al., 2005). 
This declined oxidative phosphorylation can lead to decreased ATP levels in cells under 
conditions blocking non-oxidative ATP generation (Zanna et al., 2005; Zanna et al., 2003; 
Ghelli et al., 2003). ATP deficiency is thus thought to be one possible explanation of 
ganglion cell degeneration in vivo because the unmyelinated retinal axon sections 
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theoretically have an extraordinary high energy demand, which is reflected by enhanced 
cytochrome c oxidase activity (Carelli et al., 2004a). On the other hand, oxidative stress by 
increased superoxide concentrations may play a role, since complex I is a superoxide 
generating site of the respiratory chain. Accordingly, reactive oxygen species (ROS) 
sensitive fluorescent dyes detected higher oxidative stress in mutant cybrid cells (Wong et 
al., 2002). The decrease in complex I derived ATP production, especially under stressful 
conditions, and a chronically increased oxidative stress may be the primary responsible 
factors. ATP deficiency in certain 143B.TK(-) cybrid constructs of LHON mutation have 
shown to play a vital part in the pathology of the disease which seems to modify the 
oxidative stress, and the balance between the two modes of cell death (Baracca et al., 2005; 
Carelli et al., 2004b; Ghelli et al., 2003; Zanna et al., 2003). In addition, calcium overload in 
the cytoplasm (e.g. following over-excitation) and the mitochondrial matrix may enhance the 
oxidative stress and thereby increase the probability of opening of mtPTP followed by the 
release of cytochrome c and apoptosis (Kantrow and Piantadosi, 1997). The declining 
defensive strength of cellular protection with age and environmentally induced oxidative 
stress can further provoke the onset of the disease (Kasapoglu and Ozben, 2001, Head et al., 
2002). The oxidative stress in the LHON cybrids has also been previously discussed 
(Floreani et al., 2005). The tissue specific features of retinal ganglionic cells (RGC) may 
determine the consequence of the disorder. The high energy demanding initial unmyelinated 
portion of the axons carry a high load of mitochondria and the axonal transport of 
mitochondria, a process fuelled by mitochondrial ATP, seems to be a crucial step in the 
functioning of the system. Therefore any bioenergetic defect along with excessive oxidative 
stress can result in damage to cells, possibly due to triggering of apoptotic pathways 
(Carelli et al., 2004b). 
 
Another possible cause for the specific damage to the optic nerve was hypothesized by 
Beretta, showing that the glutamate uptake maximal velocity was significantly reduced in all 
LHON cybrid cell lines that correlated in a mutation-specific fashion with the degree of 
mitochondrial production of ROS (Beretta et al., 2004). Their molecular and biochemical 
analyses showed that excitatory amino acid transporter 1 (EAAT1) was the most active 
glutamate transporter in their cellular model and the glutamate uptake maximal velocity was 
significantly reduced in all LHON cybrids compared with control cybrids. This observation 
is particularly relevant since EAAT1 is the major means of glutamate removal in the inner 
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retina and prevents retinal ganglion cell death (Rauen et al., 1996). Beretta concluded that the 
RGC in LHON disorder underwent excitotoxic damage induced by a defective glutamate 
transport leading to an insufficient withdrawal of retinal glutamate by Mueller cells. Under 
conditions of mitochondrial dysfunction ROS generation and the probability of mtPTP 
opening increase, and both are directly related to mitochondrial Ca
2+
 accumulation (Brookes 
et al., 2004). Evidence of a caspase independent mitochondrial pathway involved in the 
release of apoptosis inducing factor (AIF) and endonuclease G has also been shown (Zanna 
et al., 2005). There has been extensive research on the biochemical consequence of the 
mutations in LHON disorder and elucidation of pathological pathways of the disease like 
bioenergetic consequence (Carelli et al., 1997; Brown, 1999), biochemical features of the 
disease (Carelli et al., 1999), and discussion of altered mitochondrial ROS production 
rendering the retinal ganglion cells vulnerable to apoptotic cell death (Howell, 2003). On the 
other hand, research in the field of possible pharmacological intervention for the disease is 
rarely taken up.  
 
1.2.3 Cybrid Cells as model for LHON  
 
The difficulty with studying LHON disease is the dearth of an appropriate model for 
the disorder. The reason would most obviously be the unavailability of retinal or optic nerve 
tissue samples or biopsies from patients. By the time the sample or tissue is available the 
extent of degeneration is already too high. Recently a mouse LHON model, which was 
developed by the group of John Guy showed for the first time that a transfection of mouse 
retina with viral vectors, allotopically expressing a mutant human ND4 subunit, did develop 
elevated ROS production, optical nerve head swelling, apoptosis and progressive loss of 
retinal ganglion cells (Qi, et al., 2007b). These effects did not occur in mice transfected with 
human wild type ND4. This is the first true genetic animal model of LHON. The cybrid cell 
technology also provides us with a unique opportunity to study the disorder as they are 
relatively easy to produce and can be used for an initial high throughput screening of drugs. 
 
Yeast cells capable of switching from aerobic to anaerobic conditions for their survival 
needs is an example of naturally depleting mtDNA. Attempts of inducing mtDNA depletion 
experimentally in cultured cells have resulted in the so called “rho-zero (ρ0) cells” 
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(Desjardins et al. 1986). Such cells can survive under the right conditions of culture and 
nutritional support. The cybridization procedure involves depleting of mtDNA from the cells 
by ethidium bromide treatment, and finally fusing the resulting ρ0 cells with mitochondria 
rich platelets or enucleated fibroblast (obtained from patients with mtDNA mutation) with 
the ρ0 cells. With time the donor mtDNA will repopulate the ρ0. Thereafter, removing the 
nutritional supplements supporting the survival of ρ0 cells would naturally select the properly 
cybridized cells. The cybrid technology lends itself to study the LHON disorder, as the 
degenerating optic nerve is generally not accessible until the death of the patient, by which 
time the severity of the ailment is to its maximum with degeneration to full extent. In 
addition, the model allows a direct comparison of cell clones with mutant or wild type 
mtDNA, but containing identical nuclear DNA. The model could also provide a valuable tool 
to assess and correlate to other diseases of a possibly similar pathology e.g. Parkinson’s, 
Alzheimer’s, and Huntington’s disease. 
 
1.3 Role of calcium 
The role of calcium can not be ignored in the pathology of mitochondrial disorders as 
mitochondria are the primary calcium buffering organelles. With over-excitation, especially 
in neurons, cells can undergo a state of increased cytosolic calcium levels, which can act as a 
signal for apoptosis and cell death by its uptake into the mitochondria. The pathway of 
calcium in the mitochondria starts primarily through voltage dependent anion-selective 
channel (VDAC) in the OMM (Gincel et al., 2001; Rapizzi et al., 2002) and then through the 
uniporter in the IMM (Kirichok et al., 2004) (Figure 3). The molecular nature of the uniporter 
remains unknown but it is identified as highly selective for calcium ions (Ca
2+
). The driving 
force for uptake of Ca
2+
 comes from a fact that the mitochondrial membrane potential is 
highly negative and can quickly take up cations. This energy independent uptake 
nevertheless causes depletion of ATP by hydrolysis of ATP to drive H
+
 accumulation to 
regenerate the membrane potential through the reversal of H
+
-ATPase (Jacobson and Duchen 
2004). The calcium entering the mitochondria is a stimulus for the respiration by acting on 
the Ca
2+ 
sensitive mitochondrial dehydrogenase which increases the production of hydrogen 
ions to drive the maintenance of the negative membrane potential as well as the production of 
ATP (Denton and McCormack, 1986). Increased matrix calcium also interacts with 
cyclophilin D (which is a component of the mtPTP). Also ROS (Starkov et al., 2004) and 
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free fatty acid (Scorrano et al., 2001) generation are promoted by a rise in mitochondrial 
Ca
2+
. These factors further promote the formation of mtPTP. The mtPTP is proteinaceous and 
composed of three important proteins, namely voltage dependent anionic channel (VDAC) at 
the OMM, adenosine nucleotide translocase (ANT) at the IMM, and cyclophilin D at the 
matrix side (Tsujimoto et al., 2006; Crompton, 1999). The mtPTP-opening causes dissipation 
of the mitochondrial membrane potential with the release of Ca
2+
 and accumulation of solutes 
in the mitochondrial matrix. Local Ca
2+
 transfer between adjoining domains of the 
endoplasmic / sarcoplasmic reticulum (ER/SR) and mitochondria allows ER/SR Ca
2+
 release 
to activate mitochondrial Ca
2+
 uptake and evoke a matrix Ca
2+ 
rise. High matrix Ca
2+
 thereby 
exerts control on several steps of energy metabolism and synchronizes ATP generation with 
cell functions. However, under conditions of high calcium loads and oxidative stress, calcium 
signal propagation to the mitochondria may also ignite a cell death program through 
permeability transition, facilitated by a pore formed in the inner membrane. This occurs 
IMM 
OMM 
ANT 
UP 
VDAC 
Ca2+ 
Ca2+ 
Inter membrane space 
Mitochondrial matrix 
Cytosol 
CyP D 
Ca2+ 
Figure 3: The components of the mtPTP and the dynamics of calcium uptake in the mitochondria (figure modified 
according to Crompton, 1999). OMM, outer mitochondrial membrane; IMM, inner mitochondrial 
membrane; VDAC, voltage gated anionic channel; ANT, adenine nucleotide translocase; Cyp D, 
cyclophilin D; UP, calcium uniporter. 
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when the Ca
2+
 release from the ER/SR is enhanced or is coincident with sensitization of the 
mtPTP (Hajnoczky et al., 2006). Recent studies have also shown that several pro-apoptotic 
factors, including members of the Bcl-2 family proteins and ROS regulate the Ca
2+
 
sensitivity of both the Ca
2+
 release channels in the ER and the mtPTP in the mitochondria 
(Mathai et al., 2005). The loss of the balance between plasma membrane Ca
2+
 influx and 
Ca
2+
 export leads to a sustained elevation in cytosolic Ca
2+
 from 100 nM to ≥ 1 μM, inducing 
a progressive increase in mitochondrial Ca
2+
 uptake. When large quantities of Ca
2+
 are 
accumulated in the mitochondrial matrix, Ca
2+
 interacts with cyclophilin D to induce opening 
of the mtPTP (Basso et al., 2005). Furthermore, the rise in mitochondrial Ca
2+
 stimulates the 
generation of factors, including ROS and free fatty acids, which also promote the opening of 
the mtPTP (Starkov et al., 2004; Scorrano et al., 2001). Opening of the mtPTP causes 
dissipation of the mitochondrial membrane potential (ΔΨm) and release of Ca
2+
. If the 
cytoplasmic Ca
2+
 overload persists, the mtPTP stays open and allows accumulation of solutes 
in the mitochondrial matrix. This in turn, leads to expansion of the matrix space and to 
rupture of the OMM, giving rise to release of the intermembrane space content (Green and 
Kroemer 2004). The formation of the pore leads to permeabilization and release of pro-
apoptotic proteins from the mitochondria to the cytosol. Finally, impairment of the 
mitochondrial function and activation of cytoplasmic mechanisms by the released 
mitochondrial factors lead to execution of the cell.  
 
1.4 Minocycline as a potentially protective drug 
Minocycline (Figure 4) is a semi-synthetic second generation tetracycline antibiotic. It 
is effective against both, gram negative and gram positive infections and has been in use for 
over four decades with an acceptable safety profile. Because of its lipophilic nature, the 
bioavailability of this drug in the central nervous system is quite high, and it has been shown 
apart from its antimicrobial actions, to be effective in various models of neurodegenerative 
disorders like Parkinson’s disease (Du et al., 2001; Wu et al., 2002), Huntington’s disease 
(Chen et al., 2000), spinal cord injury (Yune et al 2007; Festoff et al., 2006) and ALS (Yong 
et al., 2004). The first neuroprotective effect of minocycline was observed in models of 
global and focal cerebral ischemia (Yrjanheikki et al., 1998 and 1999) and traumatic brain 
injury (Sanchez et al., 2001). Currently minocycline is under clinical investigation for stroke 
(Lampl et al., 2007), spinal cord injury (Fehlings and Baptiste, 2005), ALS (Pontieri et al., 
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2005; Gordon et al., 2007), Huntington’s disease (Bonelli et al., 2004), and Parkinson’s 
disease (NET-PD, 2006). Although there are contradictory or inconclusive results, 
minocycline still remains one of the most interesting potential neuro-pharmaceuticals for 
clinical trials because of its broad spectrum of protective actions and good tolerability 
(Gordon et al., 2007; Keilhoff et al., 2007; Mievis et al., 2007; Fernendez-Gomez et al., 
2005b). 
 
The two mechanisms of action of minocycline as a neuroprotective agent are mainly 
postulated to be due to its anti-inflammatory and anti-apoptotic properties. The drug has anti-
inflammatory effects attenuating ischemic injuries, endogenous IgG exudation, and the 
accumulation of neutrophils and macrophage/microglia. In addition, it also inhibits 5-LOX 
(lipooxigenase) expression and the production of leukotrienes (Chu et al., 2007). It has been 
shown to benefit in spinal cord injury by virtue of its anti-inflammatory property and 
inhibiting microglial activation (Festoff et al., 2006; Beattie, 2004). The anti-inflammatory 
effect of the drug has also been demonstrated in humans by its benefit in rheumatoid arthritis 
(O’Dell et al., 2001). Besides these effects, minocycline also possesses anti-oxidant 
properties (Kraus et al., 2005) and inhibition of neutrophil–mediated tissue injury by 
inhibiting neutrophil migration and suppressing formation of oxygen radicals (Elewa et al., 
2006; Gaber et al., 1991). It was also shown to be a scavenger of peroxynitrite (Whiteman 
and Halliwell, 1997). Minocycline also inhibits the release of nitric oxide most probably by 
suppressing the expression of nitric oxide synthase (Amin et al., 1996; Lee et al., 2004).  
 
Recently the protective effect of minocycline has been suggested to involve the 
mitochondrial dependent pathway. The anti-apoptotic effect of minocycline was observed in 
superoxide dismutase 1 mutant mice, where it delayed the progress of ALS like syndrome 
Figure 4: Chemical structure of 
minocycline 
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and also inhibited the release of cytochrome c from the mitochondria, both in vivo and in 
vitro (Zhu  et al., 2002). It inhibits both, caspase-dependent and caspase-independent 
mitochondrial cell death and release of mitochondrial pro-apoptotic proteins (cytochrome c 
and SMAC / DIABLO) in Huntington striatal-cell model (Wang et al., 2003). An 
upregulation of Bcl-2 expression by minocycline and the abolishment of its anti-apoptotic 
action by Bcl-2 antisense was also reported (Wang et al., 2004). Furthermore, it blocks the 
release of cytochrome c in polyglutamine induced cell death in striatal neurone cell lines and 
influences the swelling induced by calcium. Other than interfering with mitochondrial 
apoptotic pathways minocycline has been shown to exert its protective effects in various 
CNS disorders by virtue of its antioxidant properties (Jordan et al., 2007), its anti-
inflammatory effects (Stirling et al., 2004; Tomas-Camardiel et al., 2004), modulation of 
intracellular pathways such as PI3K/Akt (Pi et al., 2007), and mitogen-activated protein 
kinases (MAPK) (Wei et al., 2005; Tikka and Koistinaho 2001). Possible pharmacological 
application of minocycline in LHON has not been reported so far. Studying in a cybrid cell 
model of LHON disorder, the effects of minocycline on parameters of mitochondrial 
mediated cellular degeneration induced by thapsigargin (TG) can provide an initial glimpse 
of possible intervention for the disease.  
 
1.5 Aim of the study 
The neurodegeneration in LHON disorder is associated, in effect of complex I 
dysfunction, with high oxidative stress and energy metabolism imbalance (Qi et al., 2007a; 
Floreani et al., 2005; Zanna et al., 2005; Battisti et al., 2004; Ghelli et al., 2003; Zanna et al., 
2003). Investigations for a treatment or pharmacological intervention of the disease, 
however, are infrequently put under focus. Our hypothesis is that under the biochemical 
circumstances due to the mutation causing LHON disorder, cell death can occur through 
mitochondrial pathways involving the mtPTP. The mtDNA mutation in LHON and its 
metabolic consequence provides an ideal circumstance for mtPTP to be formed under 
stressful conditions, which would lead to cell death by either caspase-dependent or caspase-
independent apoptosis. Main objectives included:  
 
1. To investigate the involvement of mitochondrial permeability transition in a cell 
death model of LHON cybrids 
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2. Establishing a cell culture based model for LHON as a pharmacological tool for 
initial drug screening  
3. Devising pharmacological intervention to prevent cell death in LHON cybrids 
4. Investigating possible effectiveness of antioxidants and mtPTP blockers in treatment 
of LHON 
 
For the above stated objectives, we induced a calcium deregulation in the LHON 
cybrids using thapsigargin to provoke the opening of the mtPTP, and investigated the effect 
of minocycline (Figure 5). Minocycline was chosen for the study because it has been 
demonstrated to be an effective anti-apoptotic, anti-oxidant agent, and an effective 
neuroprotective in a variety of neurodegenerative disease models, in animals as well as in 
humans, and therefore qualifies as a good candidate to test in LHON disorder. 
Figure 5: Diagram representing working hypothesis of the model and possible protective action of 
minocycline. 
oxidative stress 
Complex I defect 
Overexcitation 
Ca
2+ 
TG 
Release of 
pro-apoptotic 
proteins 
Cell Death 
Minocycline 
? ? ? 
? 
Calcium uniporter 
mtPTP 
Downstream 
caspases and 
apoptotic event 
? 
Materials and Methods  15 
2. MATERIALS AND METHODS 
 
2.1 Chemicals, cell lines and culturing media  
All chemicals enlisted in Table 1 were handled and stored as described by the 
manufacturer’s protocol. 
 
Table 1: Used chemicals and corresponding suppliers 
 
Chemicals        Firm / company 
 Active-caspase-3 antibody      Epitomics  
 AIF antibody Rabbit monoclonal [E20]     Abcam 
 ATP Bioluminescence Assay Kit CLS II    Roche  
 Bicinchoninic acid (BCA) method kit for protein measurement     Pierce Biotech 
 Bovine Serum Albumin      PAA 
 Caspase-3 antibody H-277:(sc-7148)      Santa Cruz Biotech 
 cyclosporin A (CsA)        Alexis 
 cyclosporin H (CsH)       LKT labs  
 Dulbecco’s modified Eagle’s medium (DMEM)    Sigma 
 DMSO         Merck 
 Foetal calf serum       PAA Laboratories 
 Formaldehyde (for formalin solution)     Merck 
 Goat Serum        PAN 
 Goat anti Rabbit secondary Antibody – Alexa 488   Molecular Probes 
 Fura-PE3-AM         Sigma 
 H2DFFDA          
      (5-(and-6)-carboxy-2',7'-difluorodihydrofluorescein diacetate)   Molecular Probes 
 Immu-Mount        Thermo Scientific 
 L - glutamine.         PAA Laboratories 
 Minocycline         Sigma  
 Mitotracker green,        Molecular Probes 
 Mitotracker Orange       Molecular Probes 
 MTT (methylthiazolyldiphenyl-tetrazolium bromide)    Sigma 
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Chemicals (cont.)       Firm / company   
 penicillin/streptomycin        PAA Laboratories 
 pluronic acid        MobiTec 
 protease inhibitor cocktail (Complete mini)     Roche  
 Roti®Load1        Roth GmbH 
 Sodium Azide        Serva 
 Sodium pyruvate        PAA Laboratories 
 Thapsigargin          Molecular Probes 
 TMRM (tetramethyl rhodamine methyl ester)     Molecular Probes 
 Triton         Ferak 
 Uridine         Sigma 
 Z-VAD-FMK        MBL international 
 
 
2.1.1 Thapsigargin  
 
Thapsigargin (TG, Figure 6) is a specific inhibitor of smooth endoplasmic reticulum 
(ER) Ca
2+
 ATPase (SERCA) and an important tool for studying Ca
2+
 stores. High 
concentrations of TG affect mitochondrial functioning, induce Ca
2+
 efflux and sensitize 
mitochondria to agents and conditions which induce permeability transition (Vercesi et.al, 
1993; Hoek et.al, 1997). It has been assumed that TG promotes mitochondrial permeability 
transition by increasing the cytosolic calcium and therefore enhancing the mitochondrial 
matrix Ca
2+
 thereby increasing the sensitivity of the cell to undergo apoptosis. However, 
Korge et al. showed that the induction of MPT by TG can also be a result of a direct action 
not involving the increase of cytosolic calcium (Korge and Weiss, 1999). 
Figure 6: Chemical structure of 
Thapsigargin 
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The release of Ca
2+
 from the endoplasmic stores accounts for its most popular use. 
This however is achieved indirectly by preventing the pumps from counterbalancing the 
passive Ca
2+
 leak from the stores to the cytosol. Thus an appreciable rate of calcium leak, in 
addition to the presence of thapsigargin sensitive SERCA, is required for its action. If under 
a certain set of experimental condition, where the calcium leak is slow, on the time scale the 
peak Ca
2+
 spikes are not being achieved, the Ca
2+
 release can be afforded by calcium 
releasing agents (IP3, caffeine, acetylcholine etc).  
 
2.1.2 Cyclosporin A  
 
Besides its immunosuppressive action cyclosporin A (CsA, Figure 7) is considered as 
a potent inhibitor of the permeability transition pore compared with Mg
++
 and ADP (Zoratti 
and Szabo et al., 1995; Broeckemeier et al., 1989). CsA by interacting with cyclophilin (the 
inner component of the pore) prevents its translocation to ANT (adenine nucleotide 
translocase) and eventually inhibits the formation of the 
lethal pore (Nicolli et al., 1996). In liver and heart 
mitochondria CsA protection depends on the extent and 
magnitude of Ca
2+
 loading and the presence of external 
Mg
++ 
(Bernardi et al., 1992). CsA has been used to identify 
the activation of the mtPTP as a crucial factor leading to 
apoptosis and cell death (Zamzami et al., 1996). As a 
neuroprotective CsA ameliorates mitochondrial 
depolarization suggesting mtPTP involvement in 
excitotoxicity (Nieminen et al., 1996; Schinder et al., 
1996; Vergun et al., 1999). It is one of the most frequently 
used research tool for studying mtPTP. 
 
 
2.2 Cell lines and Culturing  
NT2/D1 human teratoma derived cell lines were used as the parental controls and 
were obtained from ATCC (American Type Culture Collection). Cybrid cells with a G to A 
point mutation at the 11778 base pair of the mitochondrial DNA (which affects the amino 
Figure 7: Chemical structure of 
Cyclosporin A 
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acid sequence of the ND4 subunit of complex I in the respiratory chain) were used as the 
LHON disorder model. The cybrid cell line was a generous gift from G. A. Cortopassi 
(Department of Molecular Biosciences, University of California Davis, Davis, CA 95616, 
USA). All cells were stored in a cryogenic solution under liquid nitrogen.11778 LHON 
cybrid cells and NT2 cells were cultivated in DMEM (high glucose, D 5648- Sigma). For 
propagation, cells were washed once with PBS, trypsinized and suspended in the culture 
medium. The suspension was spun down in a centrifuge at 1500 rcf for 5 minutes and the 
pellet re-suspended in fresh medium. The cell density in the suspension was counted with a 
Neubauer chamber and cells were plated at the required density (approximately 10
5
 cells per 
ml) in incubating flasks or onto sterile glass coverslips. In both the cell lines, treatments 
with minocycline or CsA were done 30 minutes prior to instillation of thapsigargin. 
 
2.2.1 Culturing media and buffers 
 
Culturing media (1L) 
 DMEM (high glucose, D 5648- Sigma) 13.4 g/L 
 Sodium pyruvate 110 mg/l 
 NaHCO3 1.5 g/l 
 Foetal calf serum 100 ml/l 
 Uridine 50 mg/l 
 L-glutamine (200mM) 10 ml/l 
 Penicillin (10 units/ml) / streptomycin (10 µg/ml) 
 Distilled water adjusted until 1 liter 
The mixture was sterile filtered, stored at 4°C and used within 1 month from 
the day of reconstitution. 
 
PBS 
 Na2HPO3 ● 12 H2O 295 mg/l 
 KH2PO4 240 mg/l 
 KCl 200 mg/l 
 NaCl 8 g/l 
 Distilled water up to 1 liter 
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pH adjusted to 7.4 with HCl 
 
TBS 
 Tris 24.2 g/l 
 Nacl 80 g/l 
PH was adjusted to 7.6 with HCl 
 
HBSS solution 
 NaCl 8,006 g/l 
 KCl 373 mg/l  
 CaCl2 205 mg/l  
 Glucose 991 mg/l 
 Hepes 4.76 g/l 
 KH2PO4 81 mg/l 
 K2HPO4 10.45 mg/l 
 NaHCO3 840 mg/l 
 MgCl2 182 mg/l 
pH was adjusted to 7.4 with NaOH 
 
2.2.2 Poly-D-lysine coating 
 
For better adherence of cells to the plastic or glass surfaces coated with Poly-D-lysine 
(PDL) were used. Each sterile coverslip were first kept in a sterile Petri dish and mounted 
with a 1 ml drop of PDL solution (0.1 % solution of poly-D-lysine was prepared by 
dissolving 1 mg of poly-D-lysine in 1 ml of 0.15 M boric acid prepared in PBS) at the 
centre of the coverslip such that the drop covers the whole area of the coverslip without 
running onto the Petri dish. The coverslips along with the PDL solution were then kept at 
room temperature under a sterile laminar flow hood for 1 hour. Finally, the droplets were 
sucked off and the coverslips washed once with sterile water. PDL coatings were kept in a 
sterile incubator and could be used 24 hours later. 
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2.3 Cell viability assay  
A colorimetric test, methylthiazolyldiphenyl-tetrazolium bromide (MTT) reduction 
assay was used to assess cell viability. This homogeneous colorimetric assay is based on the 
conversion of the tetrazolium salt MTT, a pale yellow substrate, to formazan, a purple dye 
(Figure 8). This cellular reduction reaction involves the pyridine nucleotide cofactors 
NADH/NADPH and is only catalyzed by living cells. The formazan product has a low 
aqueous solubility and is present as purple crystals. Dissolving the resulting formazan with 
a solubilization buffer permits the convenient quantification of product formation. The 
intensity of the product color, measured at 550 - 620 nm, is directly proportional to the 
number of living cells in the culture. 
 
LHON cybrid cells and NT2 cells were grown in a 24 well plate (approximately 
5 x 10
4
 cells per well) for 24 hours before an apoptotic stimulus with TG was given for a 
duration of 12 hours. A dose response curve of thapsigargin at concentrations of 100 nM, 
500 nM, 1 µM, 2.5 µM, and 5 µM was plotted to establish the LD50 of the same. In another 
experiment a general caspase inhibitor, z-VAD-FMK, was used to establish the nature of 
cell death. Treated groups (n=12 in each case) were incubated with the drug 30 minutes 
prior to the apoptotic stimulus. After incubation the medium was replaced by 0.5 ml of 1 
mg/ml MTT solution in sterile PBS for 1 hour. The formazan formed by the mitochondria 
of viable cells was then dissolved in DMSO (dimethyl sulphoxide) and the optical density 
of the solution measured on an ELISA plate reader at 570 nm. Cultures were tested for the 
survival of cells with different concentrations of minocycline (50, 75, 100, 125, 150, and 
Figure 8: MTT reduction to formazan 
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200 µM) and CsA (1, 2, 3, and 5 µM) against TG-induced apoptosis. The percentage 
survival was calculated by taking the arithmetic mean of control values as reference.  
 
2.4 DAPI staining  
Specific fluorescent staining of the nuclei was done using DAPI (4’,6-Diamidine-2-
phenylindole dihydrochloride). The dye binds selectively to DNA and forms strongly 
fluorescent DNA-DAPI complexes with high specificity. On adding DAPI to cell culture it 
is rapidly taken up into cellular DNA yielding highly fluorescent nuclei and no detectable 
cytoplasmic fluorescence. If the cells are apoptotic a characteristic nuclear condensation can 
readily be detected. 
 
Working solution of DAPI was used as 1 µg/ml dissolved in methanol. The cells were 
plated on the PDL coated coverslips at an approximate density of 2×10
5
 and allowed to 
grow for 32 hours. Cells were then treated with thapsigargin for 8 hours, washed with PBS 
and methanol after which they were incubated with the working solution of the dye for 15 
minutes at 37°C. The coverslips were then washed with methanol and mounted onto the 
slides. The slides were left out to dry overnight. Axiophot fluorescence microscope (Karl 
Zeiss) was used to image the nuclear morphology in both cell lines with and without 
thapsigargin treatment.  
 
2.5 Immunocytochemistry 
Immunocytochemistry was done to visualize the release of AIF from the mitochondria 
and its translocation to the nucleus. After incubating the cells with thapsigargin the 
coverslips were incubated with 40 nM Mitotracker Orange for 30 minutes at 37ºC in 
HEPES buffer and thereof fixed with 4% formalin for 30 minutes. The coverslips were then 
washed 3 times with PBS solution for 10 minutes each. The culture was blocked with 10% 
serum and incubated overnight at 4°C with the primary AIF antibody diluted (1:500) in 10% 
serum containing 0.3% Triton and 0.1% sodium azide. The next day 3 times washing with 
PBS was given, after which the culture were again blocked with Bovine serum albumin 
(BSA) in PBS for 30 minutes. Cells were then incubated with the anti-rabbit-Alexa488 
Materials and Methods  22 
conjugated secondary antibody diluted (1:500) in 0.2 % BSA in PBS for 4 hours in the dark 
at 37 °C or overnight at 4 °C, after which thrice washing with PBS was given. For labelling 
the nucleus of the cells the same were then incubated with DAPI as explained in the DAPI 
staining protocol above. Finally the coverslips were mounted onto the slides with a 
mounting solution and stored at 4 °C protected from light. 
 
The slides were imaged with Zeiss Axiophot fluorescence microscope with green (BP 
546 nm), blue (BP 450 nm – 490 nm) and ultra violet (BP 365 nm) filters corresponding to 
mitotracker Orange, Alexa 488 complex, and DAPI staining, respectively. The pictures 
were taken with an Axiocam using Axiovision software. 
 
2.6 ATP measurements 
ATP measurement was performed using a bioluminescence ATP assay kit (ATP assay 
Kit CLS II, Roche). According to the manufacturer’s protocol, the ATP dependency of the 
light emitting luciferase catalyzed oxidation of luciferin was used for the measurement of 
extremely low concentrations of ATP.  
 
Standard curve 
ATP standards were appropriately diluted to give the following dilutions: 
1 µM ATP 
0.5 µM ATP 
0.25 µM ATP 
0.125 µM ATP 
0.0625 µM ATP 
The standard curve was plotted and was subjected to regression analysis.  
ATP measurement buffer  
 Tris  12.114g/l 
 EDTA 1.169 g/l 
pH adjusted to 7.75 
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Samples were collected from both NT2 cell line and LHON cybrids at 1, 1.5, and 2 
hours after incubation with thapsigargin. The effect of minocycline was also studied in this 
model to observe changes, if any, on the ATP levels under the influence of the drug.  
 
Cells were trypsinized and spun down at 1000 g for 5 minutes. The supernatant was 
discarded and the pellet re-suspended in PBS. The cells were again centrifuged at 1000 g for 
2 minutes, the supernatant replaced with boiling ATP measurement buffer, and incubated 
for another 2 minutes at 100 ºC. Samples were centrifuged at 1000 g for 1 minute and the 
supernatant was transferred to a fresh tube. An appropriate dilution of the supernatant was 
then mixed with luciferase reagent and measured for luminescence intensity using a TD-
20/20 luminometer. The calibrated luminescence and regression of the standards was 
applied to get the ATP concentrations from the sample readouts. These values were then 
adjusted to the protein level of the samples. 
 
2.7 Calcium imaging  
Cells were cultured on sterile coverslips and visualized for live cell imaging 32-48 
hours later. Fura-PE3-AM with an end concentration of 5 µM was used as fluorescent 
ratiometric calcium indicator (stock solution prepared in a 20 % pluronic acid in DMSO). 
Microscopy was done with Meta Fluor software on the Zeiss Axiovert 100M Pascal 
confocal microscope with Visitron Systems GmbH setup. The ratiometric imaging required 
the use of two wavelengths (340 nm and 380 nm). At absorption wavelength of 340 nm the 
dye’s fluorescence intensity increases as the amount of Ca2+ binding to the dye increases. 
20 minutes 
HBSS Buffer HBSS Buffer 
1 mM Acetylcholine 
1 µM TG 
 
Figure 9:  A schematic diagram of calcium imaging experiment. Treatments with minocycline and CsA are 
given 30 minutes prior to imaging and throughout the perfusion. 
Materials and Methods  24 
On the other hand the inherent fluorescent intensity of the dye increases with decrease in the 
binding of Ca
2+
 if the incident wavelength is 380 nm. The fluorescent ratio of 
340 nm/380 nm therefore amplifies the signal of calcium within the cell. Cells were 
incubated with the dye at a concentration of 5 µM for 30 minutes. After the incubation the 
cells were washed with HBSS once to drain away excess dye. The coverslips were then 
placed in a fixed chamber and mounted on a thermostatic metallic grid (maintained at 
37 ºC) on the microscope and perfused with HBSS at 37 ºC with or without the drug 
investigated. For evaluating the effects of minocycline and CsA the cultures were incubated 
with the respective drug for 30 minutes prior to the commencement of the experiment. At 
the beginning of the experiment, buffer was perfused through the culture for 3 minutes to 
get a stable baseline after which the experimental recording was started. The optimized 
experimental setup is schemed in Figure 9. Acetylcholine was used to induce calcium 
release after which TG at a concentration of 1 µM was perfused to completely and 
irreversibly inhibit the reuptake of calcium back to the endoplasmic stores. The change in 
the cellular calcium was measured by the ratio of the two fluorescent intensities at 340 nm 
and 380 nm, which corresponds to the calcium bound and the native form of the dye, 
respectively. 
 
2.8 Mitochondrial depolarization  
Cells were cultured on Poly-D-lysine coated coverslips for 24 hours and 
mitochondrial depolarizing experiments were conducted in cell culture medium which was 
deficient in serum. Tetramethyl rhodamine methyl ester (TMRM, at an end concentration of 
100 nM, stock solution prepared in a 20 % pluronic acid in DMSO) was used to assess the 
mitochondrial depolarization after TG-induced apoptosis, and Mitotracker Green (at an end 
concentration of 160 nM, stock solution prepared in a 20 % pluronic acid in DMSO) for 
simultaneously visualizing the total population of mitochondria. After eight hours of 
incubation with 1 µM TG, with or without 100 µM minocycline or 3 µM CsA, the 
coverslips were incubated with Mitotracker Green and TMRM for 30 minutes and 
15 minutes respectively, and view fields were selected randomly for taking pictures with the 
Zeiss Axiovert 100M Pascal confocal microscope. Cells from different coverslips were 
counted for those stained with mitotracker green (total number of cells) and for those that 
were additionally stained with TMRM (cells with conserved mitochondrial membrane 
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potential). From each treatment group (n = 5-6) at least 4 pictures were taken and pooled for 
analysis. Percentage of cells with intact mitochondrial membrane potential was calculated 
by dividing the number of TMRM stained cells by the total number of cells stained with 
Mitotracker Green. 
 
2.9 Protein determination 
For western blotting protein measurement was performed by using commercially 
available kit (BCA
TM
 protein assay kit, Pierce) based on the bicinchoninic acid (BCA) 
method (Smith et al., 1985). 20 µl of the sample or standard was mixed with 1ml of 
working solution and kept at room temperature for 30 minutes. The optical density of the 
solution was read at 570nm. Standard curve was constructed using standard solution of BSA 
at concentrations 100, 200, 400, 600, 800, 100, and 1200 mg/L. The regressed curve 
obtained by the standards was used as reference for the protein readout in the samples. 
 
For ATP measurements Bio-Rad DC (detergent compatible) colorimetric protein 
assay was used. All regents were prepared according to the instructions of the manufacturer. 
The reaction is based on the well-documented Lowry assay (Lowry et al. 1951). The 
BioRad DC protein assay is measured at 650–750 nm with a standard laboratory 
spectrophotometer or microplate reader. The standard protein was in the form of BSA 
solutions with concentrations 0.0, 0.1, 0.25, 0.50, 1.0, 1.5, 2.0, and 3.0 mg/l. A standard 
curve was plotted with the help of regression and the protein concentrations of the samples 
were extrapolated. 
 
2.10 Western blotting  
The ratio of active-caspase-3 to pro-caspase-3 (aC3/pC3) was calculated by analysis 
of Western blots of LHON cybrid cells and the NT2 cell line subjected to TG-induced 
apoptosis. The time point of sample collection was 8 hours after incubation with 1 µM TG 
with or without treatments (n=5 cultures for each treatment). The cells were scraped and 
then spun down at 1500 g for 5 minutes. Pellets were re-suspended in 0.05 M sodium 
phosphate solution containing protease inhibitor cocktail and transferred to an Eppendorf 
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tube and spun again. The pellets were then homogenized with a Teflon tip homogenizer and 
spun again at 14000 rcf for 5 minutes. The supernatants obtained were taken for analysis.  
 
Separation Gel buffer 
 Tris 1.5 M 
 SDS 0.4 % 
 EDTA 2.9 % 
pH adjusted to 8.8 with HCl 
 
Collection Gel buffer 
 Tris 0.5 M 
 SDS 0.4 % 
 EDTA 2.9 % 
pH adjusted to 6.8 with HCl 
 
Electrophoresis Buffer 
 Tris 3.03 g/l 
 Glycine 14.4 g/l 
 SDS 1 g/l 
 
Blotting buffer (2L) 
 Tris Base 4.543 g 
  Glycine 21.6 g 
 SDS 4 ml of 10 % SDS solution 
 Methanol 400 ml 
 
Blocking solution 
5 % solution of low fat Milk protein powder dissolved in TBST (TBS with 0.1 % 
Tween) 
 
Gel was casted in a Hoeffer gel caster. Ten teeth comb was used to cast the wells in 
the loading gel with a sample volume of not more than 20 µl per well. Samples were first 
solubilized with a solubilizer (Roti®-load1). 
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Electrophoresis was done on gradient acrylamide gel (5-20%). Protein was then 
transferred onto a nirtrocellulose paper by wet blotting transfer with the help of a blotting 
apparatus at about 80 mA for 90 minutes. The blots were washed three times, five minutes 
each, and blocking was done for 4 hours at room temperature. Primary antibodies (Caspase-
3 antibody was used with 1:200 dilution and active-caspase-3 antibody at a dilution 1:500) 
were incubated with the blot at 4ºC overnight, washed with PBS 3 times (each for 5 
minutes) and incubated with horseradish peroxidase conjugated secondary antibody for 2 
hours at room temperature. After a minute of contact with the reconstituted Western blotting 
detection reagents (ECL
TM
 Amersham) the blots were developed using a 
chemiluminescence film (Hyperfilm ECL
TM
, Amersham). Band intensities of the blots 
obtained with Quantity one (1D analysis software from BioRad) were subjected to 
calculation of  aC3/pC3 ratio. The ratios of normal untreated groups were normalized to a 
value of 1. 
 
2.11 DFF imaging  
5-(and-6)-carboxy-2’,7’-difluorodihydrofluorescein diacetate (carboxy-H2DFFDA) is 
a photo-stable congener of the widely used intracellular ROS detecting dye 
dichlorofluorescein (DCF) which fluoresces upon oxidation (Jakubowski and Bartosz, 
2000). Experiments were performed on cells cultured on coverslips, incubated with the dye 
(stock solution prepared in a 20 % pluronic acid in DMSO) for 1 hour and the respective 
drugs for 30 minutes prior to imaging and mounted onto the confocal microscope in a 
thermostatic chamber. The medium was replaced with 990 µl of modified Locke’s solution 
(7.58 g/l NaCl, 300 mg/l KCl, 240 mg/l CaCl2, 240 mg/l MgSO4, 340 mg/l NaHCO3, 
2.42 g/l HEPES , 1.82 g/l glucose, adjusted to pH 7.3) without and with different 
concentrations of the drug investigated. Fluorescence (excitation at 488 nm and emission at 
530 nm) was measured in living cells using a Zeiss Axiovert 100 M Pascal confocal 
microscope for at least 10 minutes. Experimental settings including the pinhole diameter, 
intensity of the laser, and the detector gain was kept uniform in all the experiments 
performed. The first 100 seconds of the measurement were used to obtain a steady baseline 
after which 10 µl of 10 mM H2O2 solution in modified Locke’s solution was injected into 
the monitored culture (final concentration of 100 µM H2O2). The regions of interest were 
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defined and the intensities of fluorescence were recorded from those particular areas. 
Analysis was conducted with subtraction of background intensities in respective cultures. 
 
2.12 Statistical analysis  
All results are expressed as mean ± S.E.M. A One-way ANOVA followed by 
Dunnett’s t test was performed to assess the difference between and within the treatment 
groups in all experiments where more than two groups were planned for comparison. For 
the results obtained by calcium imaging, the fluorescent values were collected at a time 
point of every 100 seconds after the withdrawal of calcium stimulus. For this experiment, a 
two-way ANOVA was done to assess bi-factorial treatment × time effect. A p value of F 
statistics less than 0.05 indicates that at least one pair of the treatment groups differed 
significantly in the two-way ANOVA. Bonferroni’s multiple comparison test was applied to 
test exactly which pair(s) of treatment significantly differed. Student’s t- test was used to 
evaluate whether TG induced a significant difference in the aC3/pC3 ratio between the two 
cell lines. All statistical tests were done by using GraphPad Prism 4 (GraphPad Software). 
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3. RESULTS 
 
3.1 Minocycline and cyclosporine A protect LHON cybrids against TG 
induced toxicity 
In the MTT assay the LD50 of thapsigargin in LHON cybrid cells was determined to 
be 1 µM. The dose caused significant decrease of surviving cybrids cells to below 50% 
shown as the encircled concentration (Figure 10). This concentration of TG was then taken 
in all the experiments performed thereon.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the cell viability assay TG significantly decreased the percentage of survival in 
both cell lines (In Figure 11A the viability in NT2 cell line was reduced to 71.7 ± 0.67 %, 
n=6, p<0.05 and in LHON cybrid to 49.5 ± 1.96 %, n=6, p<0.05; In Figure 11B the viability 
of NT2 cell line was reduced to 69.2 ± 0.73 %, n=6, p<0.05 and LHON cybrid to 53.7 ± 
2.68 %, n=6, p<0.05). The difference in the survival rate of LHON verses NT2 cells treated 
with TG was significant which indicated that the LHON cybrids were more sensitive to the 
apoptotic stimulus. LHON cybrids with the same mutation, but based on the 143B TK (-) 
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osteosarcoma cell line, have previously been shown to be more sensitive towards apoptotic 
stimulus (Danielson et al., 2002). The concentration response curve shows for LHON 
cybrid cells that the treatment with minocycline at concentrations of 100-125 µM prevents 
apoptosis as indicated by a higher rate of survival (Figure 11A). A minimum effective dose 
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Figure 11: LHON cybrid and NT2 cell survival assay and concentration response curve of minocycline 
(A) and CsA (B) against TG-induced cell death. * p<0.01).  
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of minocycline in the LHON cybrid cells was found to be 100 µM (78.8 ± 1.72 %, p<0.05). 
At higher doses there was manifestation of toxic effects of minocycline because the 
percentage of survival significantly decreases to 53.9 ± 3.3 % and 48.3 ± 2.3 % respectively 
at doses 150 µM and 200 µM. On the other hand however, in the parental cell lines, the 
protective effect of minocycline was not observed at any concentration. Toxic effect of 
minocycline at concentrations of 150-200 µM, as seen in the cybrid cells, were observed in 
the NT2 cell line as well. Concentration response curve of CsA in the two cell lines (Figure 
11B) showed that there is no significant increase in cell survival at any concentration in the 
NT2 cells whereas the minimum effective dose in the LHON cybrid cells was 2 µM (68.7 ± 
0.95 %, p<0.05). In addition, 3 µM CsA (74.78 ± 1.31 %) shows a significantly higher 
protection than 2 µM CsA in cybrid cells. 
 
In an additional experiment using a general caspase inhibitor z-VAD-FMK it was 
observed that neither cell line showed significant protection from TG induced decrease in 
cell viability when the general caspase inhibitor was present in the incubation media. LHON 
cybrids upon TG decreased to viability which remained unchallenged in presence of the 
general caspase inhibitor (Figure 12B). Similarly, NT2 cells showed a decrease in viability 
upon TG insult which was also unaltered by z-VAD-FMK treatment (Figure 12A). This 
suggests that the cell death induced by TG was not dependent on caspase activation. To 
validate the above stated results which suggest that apoptotic cell death is not the reason for 
the decrease in cell viability in the MTT assay we performed DAPI staining and 
activecaspase-3:procaspase-3 (aC3/pC3) Western blot of cells treated with TG to grant a 
further account for the decrease in cell viability in the MTT assay. 
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Figure 12: Cell viability assay of LHON cybrids and NT2 cells upon TG insult in presence of a general 
caspase inhibitor z-VAD-FMK 
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3.2 DAPI staining shows apoptotic nuclear morphology in TG treatment 
DAPI binds selectively to DNA forming a DAPI-DNA complex. The staining is used 
widely to study the morphology of the nucleus. An apoptotic nucleus would be visible as a 
condensed bright kernel of the cell. After 8 hours of incubation with 1 µM thapsigargin 
DAPI staining performed in both cell line showed typical apoptotic morphology of their 
nucleus. Nuclear condensation was present throughout the culture (Figure 13). This was 
rather unexpected as the cell death indicated by the MTT assay was not considered 
apoptotic due to ineffectiveness of z-VAD-FMK to protect the cells. 
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Figure 13: DAPI staining of NT2 and 11778 LHON cybrid cells shows distinctive nuclear condensation (white 
arrows) and apoptotic event in TG treatment. Scale bar of 50 µm applies to all pictures. 
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3.3 Apoptosis inducing factor translocates to the nucleus in TG treatment  
AIF translocation constitutes a hallmark of permeability transition pore induced 
caspase independent apoptosis. As the cell death in our experiment turns out to be caspase 
independent but CsA sensitive, with DAPI staining showing signs of nuclear condensation, 
it is quite possible that AIF release constitutes the major pathway of apoptosis. The 
Figure 14: Immunocytochemistry of AIF shows its translocation to the nucleus upon TG treatment in 
both cell lines. White arrows indicate presence of AIF in nucleus. 
DAPI 
Mitotracker 
Orange 
AIF 
Overlap 
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immunocytochemistry did indeed show the same to be true. TG induced a translocation of 
AIF labeling from the mitochondria to the cytoplasm and nucleus (Figure 14). The triple 
labeling of AIF antibody, DAPI and mitotracker orange shows that TG treatment causes a 
release of AIF in LHON cybrids as well as in NT2 cells, the latter showing considerably 
lower number of cells with AIF translocation than the former. Due to the nature of simple 
fluorescence microscopy a heavy load of background is visible which is because this type of 
microscopy, unlike the confocal microscopy, does not measure fluorescence from a thin 
section of the sample culture (Figure 14).  
 
3.4 Thapsigargin treatment decreases ATP levels in LHON cybrids 
Since apoptosis is an energy dependent process, the level of ATP is a critical player. 
To observe the dynamics of cellular energy in our experimental model of TG induced cell 
death luminometric analysis of ATP was conducted at different intervals of TG treatments 
in both cell lines. The ATP levels of LHON cybrids initially decreased significantly but 
reclined at 2 hours of the treatment. The NT2 cells however did not show a significant 
decline in ATP level in any of the measurements performed after thapsigargin treatment. 
0.5 hours 1.0 hour 2.0 hours 
* 
Figure 15: ATP measurements, with and without 100µM minocycline (MC), in LHON cybrids and NT2 cells 
treated with TG. A significant decline in ATP levels in the TG treated LHON cybrids is seen, but 
not in NT2 cells. 
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100 µM minocycline treatment failed to modify the ATP level changes brought by 
thapsigargin (Figure 15). A cytosolic calcium increase should ideally stimulate the 
respiratory production of ATP by enhancing the activity of calcium sensitive dehydrogenase 
and therefore increasing the production of H
+
 ions. On the other hand, calcium itself being a 
cation can render the matrix more positive and decrease the membrane potential. This is 
well visible with NT2 cells where the decrease is insignificant. LHON cells, however, 
showed a decrease of ATP production with TG insult.  
 
3.5 Minocycline and cyclosporine A alleviate calcium deregulation  
Ca
2+
 as the centre of mitochondrial apoptotic research has been shown to undergo 
deregulation upon mtPTP opening (Andrabi et al., 2004). In the visitron imaging, cells can 
be seen as small island clusters which appear as dark patches and the background appears to 
have a higher fluorescence. This is a pseudo-background effect, as the small amount of dye 
Figure 16: Pictorial representation of the LHON cybrid cells in a ratiometric calcium imaging experiment 
using Fura-PE3-AM. Both CsA and minocycline showed a lowering of the cellular levels of 
calcium after the withdrawal of the TG stimulus.  
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leaking out of the cells bind to high extra-cellular calcium (present in the buffer) and gives 
out a false fluorescence ratio. The fluorescence ratios of the cell islands change without 
significant change in the background (Figure 16). Using ROIs on individual cells we 
conducted the live cell calcium imaging to visualize the calcium dynamics in our model of 
investigation. Cybrid cells in the Ca
2+
 imaging experiment (Figure 16 and Figure 17B and 
C) exhibited a deregulation of cellular calcium upon TG perfusion after an initial 
stimulation with acetylcholine (AcCh), which was indicated by a significantly higher 
sustained cytoplasmic level of calcium above the basal level (Figure 17B and C). The 
deregulation of calcium was alleviated in the LHON cybrids by 100 µM minocycline and 
3 µM CsA (Figure 17B). After the withdrawal of the excitatory stimulus, at 600 seconds of 
recording, the calcium fluorescent ratio values in minocycline (1.013 ± 0.017; n=5) and 
CsA (1.03 ± 0.005; n=5) treated groups significantly declined as compared to the AcCh/TG 
(1.069 ± 0.004; n=5) per se group. These differences in fluorescent ratios of the respective 
treatments were maintained through rest of the recordings. Two way ANOVA of the point 
in the graph after the withdrawal of thapsigargin revealed that there was a significant 
difference between treatment groups (F(3,112)=39.01, p<0.001). In the NT2 cell line 
however, no significant differences in the fluorescent values were observed and the 
insignificant calcium deregulation induced by AcCh/TG was not significantly alleviated by 
minocycline or CsA at any time point after the withdrawal of the stimulus (Figure 17B). 
 
3.6 Mitochondrial membrane potential is conserved by minocycline 
Cells stained with mitotracker green and TMRM are represented in Figure 18. A 
typical co-staining of the two fluorescent dye reveals a yellow color on overlapping. Results 
represented in Figure 19 shows that TG induced a significant decrease in the percentage of 
cells with active membrane potential in both cell lines (NT2 cells = 92.85 ± 1.81%, p<0.05 
and LHON cybrid = 68.54 ± 1.6%, p<0.01). The degree of depolarization induced by 
thapsigargin in the two cell lines was also significantly different. The co-localization of 
TMRM and Mitotracker green, used as an indicator of functional mitochondria in 
proportion to the total population of mitochondria, was significantly increased in the 
100 µM minocycline (88.29 ± 1.8 %, p<0.01) as well as 3 µM CsA (97.38 ± 0.39 %, 
p<0.01) treated groups in LHON cybrid cells (Figure 19B) (F(2,111) = 89.25 p<0.01). 
However, neither 100 µM minocycline (87.41 ± 2.14 %) nor 3 µM CsA 
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Figure 17: Graph of the calcium imaging experiments with different treatments. (A) A general layout of the 
experimental protocol, (B) live cell calcium imaging of LHON cybrid, and (C) live cell calcium 
imaging of NT2 cells. MC = minocycline. 
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Mitotracker Green TMRM Overlap 
Control 
TG 
TG 
+ 
CsA 
TG 
+ 
Minocycline 
Figure 18: Mitochondrial membrane potential imaging by TMRM uptake in LHON cybrid cells. Cells 
were incubated with TG (1 µM) for 8 hours. Mitotracker green is taken up by all 
mitochondria, whereas TMRM stains only those that have intact membrane potential. The 
conservation of ∆Ψm by minocycline (100 µM) and CsA (3 µM) is observed when compared 
to cultures that were treated with TG alone. Scale bars are representative of 50 µm length.  
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(90.56 ± 2%) was effective in conserving the mitochondrial membrane potential loss in the 
NT2 cells treated with TG (Figure 19A.) (F(2,59) = 1.253, p=0.29). 
 
Figure 19: Percentage of cells with preserved mitochondrial membrane potential with minocycline, CsA 
and  CSH treatments after TG incubation in LHON cybrid cells and NT2 (parental cell line) as 
indicated by the uptake of TMRM. (A) percentage of NT2 cells taking up TMRM,  (B) 
percentage of LHON cybrids taking up TMRM. *p<0.05, †p>0.05 
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The multidrug resistance (MDR) inhibition effect of CsA which can prevent the 
leakage of the dye from the cytoplasm and thereby give false positives were eliminated with 
the use of its congener cyclosporine H (CsH). CsH has a similar MDR inhibiting effect as 
that of CsA (Dietel et al., 1994: Foxwell et al., 1989) without the permeability transition 
blocking effect of CsA (Teplova et al., 2000; Woodfield et al., 1998). Experimentation with 
this congener could eliminate the MDR inhibiting activity of CsA in the uptake or retention 
of TMRM after thapsigargin insult. The results clearly showed the effects of CsH to be 
significantly lower than that of CsA suggesting that the increase of uptake shown by CsA 
was not dependant entirely upon the MDR inhibition property of the drug. 
 
3.7 Active-caspase-3:procaspase-3 ratio is decreased by minocycline and 
cyclosporine A.  
 
The effector caspase-3 activation is a downstream event in apoptosis. The opening of 
permeability transition and release of proapoptotic proteins like cytochrome c is responsible 
for the eventual activation of procaspase-3 to caspase-3 (active form). Western blots of 
LHON cybrid cells treated with TG showed an increase in the ratio of aC3/pC3 suggesting 
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Figure 20: Representative Western blots of active-caspase 3 and procaspase 3 in NT2 (A) and LHON 
cybrid cells (B) following TG (1 µM) treatment for 8 hours. Cells were incubated with or 
without treatments (i.e. 100 µM minocycline or 3 µM CsA) in a serum free medium. Lane 1 = 
Control, 2 = incubation with 1 µM TG alone for 8 hrs, 3 = minocycline (100 µM) and, 4 = CsA 
(3 µM) treatment.  
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Figure 21: aC3/pC3 ratio of different groups is compared to the control (non thapsigargin treated: 
calculated as 1). Minocycline failed to significantly decrease the ratio in the NT2 cell lines but 
significantly reduced that in LHON cybrid cells. All bars represent groups treated with 1µM 
TG. Data are represented as arbitrary ratio units ± S.E.M. * p<0.05, † p>0.05. 
 
† 
an activation of the downstream apoptotic event (Figure 20 and Figure 21). Quantification 
of the blots by densitometry exhibits a significant increase in the aC3/pC3 ratio in the 
LHON cybrids (2.82 ± 0.19; n=6) treated with TG comparing to NT2 cells (1.78 ± 0.18; 
n=5). Two-way ANOVA showed a significant effect of treatments on the aC3/pC3 ratio 
(F(3,26)=19.84, p<0.01). A significant decrease in the ratio was seen in the LHON cybrid 
cells after minocycline (1.97 ± 0.16; n=7) or CsA (1.35 ± 0.23; n=7) treatments. In NT2 
cells however, minocycline (1.34 ± 0.36; n=5), or CsA (1.1 ± 0.31; n=3), failed to 
significantly decrease the TG-induced rise of aC3/pC3 ratio. 
 
3.8 Minocycline decreased the DFF fluorescence gain  
 
Investigation of antioxidant properties of minocycline shows a significant dose 
dependent decrease in the DFF fluorescence by the drug. The basal level fluorescence in the 
LHON cybrids (35.94 ± 3.13) declined significantly with 100 µM (18.86 ± 4.18), 50 µM 
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(22.43 ± 1.38), and 25 µM (24.55 ± 2.87) but not with 10 µM (26.59 ± 4.1) minocycline, 
which suggests a dose dependent lowering in the oxidative stress level. The basal level 
fluorescence decline is comparable with the basal fluorescence observed in the NT2 cells 
(23.07 ± 1.6). Vitamin C as an antioxidant also brings down the basal oxidative level in the 
cybrid cells (19.35 ± 1.54, Figure 22). Subjecting the fluorescent intensities of the first 100 
seconds of imaging to two way ANOVA between eight groups (NT2, LHON cybrids, 
LHON cybrids treated with four different minocycline concentrations, 3 µM CsA, and 
100 µM vitamin C) reveals that the oxidative stress in the LHON cybrids was significantly 
lowered in both minocycline dose dependently (25 µM, 50 µM, and 100 µM) and vitamin C 
treatment at a concentration of 100 µM. This, however, is evident with the anti-apoptotic 
dose of CsA (36.59 ± 6.39) and the lowest dose of minocycline (10 µM) (F (7,49)=4.924, 
p<0.01). A similar effect, as observed in the basal fluorescent intensities, was also seen with 
different concentrations of minocycline after H2O2 injection. An increase in fluorescent 
intensity was seen in the LHON cybrids in presence of H2O2 which significantly declined 
with minocycline and vitamin C treatment (Figure 23 and Figure 24). The live cell imaging 
shows that significant decrease in fluorescence intensities was observed with two of the 
higher but not the two lower doses of minocycline in comparison to the untreated group 
upon H2O2 injection in the culture (Figure 24 B). 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Average initial fluorescence intensities of first 100 seconds of imaging in different treatments. 
Significantly higher basal fluorescence intensity was observed in the LHON cybrid cells as 
compared to the parental NT2 cells, suggesting a higher level of oxidative stress in the cybrids.  
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Figure 23: Representative DFF fluorescence live cell imaging of LHON cybrid cells. Confocal images of LHON 
cybrid cells stimulated with 100µM H2O2 with or without 100µM minocycline treatment. The 
images are converted to pseudo color corresponding to grey scale intensities of 0-255. Lower overall 
intensities are visible in the minocycline and vitamin c treated cultures. 
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Figure 24: Comparative Graphs of DFF imaging with different treatments. (A) Comparison of DFF imaging 
fluorescence curve of NT2 cells with LHON cybrids stimulated with 100 µM H2O2 and the effect of 
CsA and vitamin C on the fluorescent intensities, (B) dose dependent decrease in DFF fluorescence by 
minocycline treatment in LHON cybrids. MC = minocycline; vit C = vitamin c. 
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4. DISCUSSION 
 
Mitochondria play a pivotal role in apoptotic signals. Other organelles like 
endoplasmic reticulum act in co-ordination with the mitochondria to initiate the apoptotic 
and cell death pathways. The endoplasmic reticulum appears to be the regulator of apoptosis 
as it is the main storehouse of cellular calcium and upon the release of these stores, calcium 
is quickly taken up by the juxtaposed mitochondria (Kim et al., 2006), which does not 
require the expenditure of ATP as it is driven by the mitochondrial membrane potential 
through the calcium uniporter in the IMM. An increase in the mitochondrial calcium results 
in an increase in the metabolic rate and production of free radicals, especially in conditions 
of respiratory chain defects. These combinations of scenarios thereby modulate the activity 
of the permeability transition (Smaili et al., 2000). Additionally, regulation of a steady state 
endoplasmic reticulum Ca
2+
 levels appears to be crucial checkpoint for Ca
2+
 dependent 
apoptosis. The involvement of deregulation of cytosolic and intra-mitochondrial calcium in 
neurodegeneration has been shown by researchers to constitute a major mitochondrial 
pathway to apoptosis through the opening of mtPTP (Jacquard, et al., 2006). 
 
In this study a cybrid cell culture model of LHON disorder was used to investigate 
possible therapeutic interventions for the disease. For this purpose our model included for 
induction of cell death, the irreversible smooth endoplasmic reticular calcium ATPase 
(SERCA) inhibitor, TG (Lytton et al., 1991). An initial LD50 study of TG shows that 1 µM 
of the substance shows approximately 50% decrease in cell viability as presented by the 
outcome of MTT cell survival assays (Figure 10). TG, along with acetylcholine (in the 
calcium imaging experiments used to cause an initial release of calcium) inhibits the 
reuptake of calcium to the endoplasmic stores and, thus, augments mitochondrial calcium 
accumulation to mimic neuronal over-excitation (Hoek et al., 1997). Calcium being a 
positive effector of mitochondrial function, stimulates respiratory pathways and leads to 
generation of ROS (especially in case of respiratory defects which are also responsible for 
lower ATP generation) creating an ideal condition for mtPTP opening (Brookes et al., 
2004). A possible therapeutic target would therefore be to lower oxidative stress along with 
blocking the mtPTP activity. We therefore investigated the effect of minocycline in the 
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aforementioned cell death model of LHON cybrids as it has been shown previously to 
possess both antioxidant and mtPTP blocking activity. 
 
4.1 Increased cell viability in LHON model upon minocycline and 
cyclosporine A treatment 
 
In the MTT cell viability assay minocycline demonstrated a significant protective 
effect in the LHON cybrid cells at a concentration of 100 µM and 125 µM in the model of 
TG induced cell death (Figure 11A). Further increase in the concentration apparently does 
not lead to a more pronounced protection against TG-induced cell death. On the contrary 
higher concentrations of minocycline (150 and 200 µM) were toxic to the cells. In the 
parental NT2 cells, however, TG had a much lower effect on decreasing the cell viability 
and minocycline was ineffective in providing protection at any tested concentration. In 
similar experiments, CsA was found to be comparatively effective in the cybrid cells at a 
concentration of 3 µM (Figure 11B). This was also observed in the calcium imaging 
experiments where the deregulation of calcium was likewise alleviated. In the NT2 cells 
however, none of the concentrations of CsA that were effective in the LHON cybrid cells, 
were found to be protective as demonstrated by the viability assay of TG treated cells 
(Figure 11 B). CsA being one of the most frequently and reliably used experimental 
inhibitor of mtPTP, these results suggest that the mtPTP may not play a significant role in 
decreasing the cell survival in the NT2 cells, whereas it does in the LHON cybrid cells.  
 
The decrease percentage viability of NT2 cells by TG treatment can be attributed to 
the ER stress response and depletion of the Ca
2+
 stores (Kitamura et al., 2003, Yoshida et 
al., 2006). This would also be true for the LHON cybrid cells. On the other hand the MTT 
cell survival assay with the general caspase inhibitor z-VAD-FMK suggests that the cell 
death induced by TG is caspase independent i.e. non-apoptotic. DAPI staining however 
shows characteristic nuclear condensation, an absolute hallmark of apoptosis. As ATP 
levels are crucial for dictating the pathway of cell death (Leist et al., 1997), the ATP 
analysis also suggests cell death to be apoptotic in nature as the levels rise after an initial 
drop. Moreover, even under diminished conditions of ATP levels, a caspase independent 
form of cell death has been reported in other LHON cybrids (Zanna et al., 2005; 
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Zanna et al., 2003). For this type of apoptosis, the release of proapoptotic molecules from 
the intermembrane space was shown to elicit LHON cell death without the need of 
activating caspase-3. On the other hand, Western blot analysis reveals that the ratio of 
aC3/pC3 increases significantly more in the LHON cybrid cells than in the NT2 cells when 
treated with TG, and this ratio is decreased by CsA treatment in the LHON cybrids but not 
in NT2 cells indicating that the permeability transition is involved in LHON cybrids. 
Minocycline also significantly decreased the ratio in the cybrid cells but not in the NT2 
cells. This is in concurrence with the results of the cell viability assay in which minocycline 
showed no significant protection at the observed concentration. On the other hand, however, 
the result of Western blotting and DAPI staining are also in conflict with the results of 
caspase inhibitor assay. The only evocative mechanism of cell death induced by TG in such 
a scenario, where the apoptosis is caspase independent, along with a suggestive involvement 
of mtPTP, would be the involvement of AIF (apoptosis inducing factor) or endonuclease G 
which are released from the mitochondria in apoptosis and translocates directly to the 
nucleus to cause nuclear condensation (van Loo et al., 2001; Daugas et al., 2000). This 
possibly also leaves other parallel mitochondrial apoptotic pathways intact, like the release 
of cytochrome c and eventually activation of downstream caspases, which explains the 
caspase-3 activation observed in western blotting. Immunocytochemistry of LHON cells 
treated with TG indeed revealed the involvement of permeability transition and the release 
of AIF from the mitochondria and its translocation to the cytoplasm and nucleus. There 
were few NT2 cells which also showed the AIF translocation which suggested that there is 
an extent of involvement of mtPTP in the parental cell line also, but, the population of such 
cells was small.  
 
In the ATP measurements the decline of ATP level upon thapsigargin treatment in 
LHON cells (Figure 15) also points to mitochondrial damage by the calcium stimulus as a 
prerequisite of permeability transition and apoptosis (Brookes et al., 2004). Conservation of 
most ATP or even a re-establishment of normal levels of the same, after an initial decrease, 
may be necessary for the apoptosome to form, and thus for apoptosis to proceed 
(Figure 15). This phenomenon would not be necessary if the main pathway of apoptosis is 
through AIF release.  
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4.1.1 Inhibition of mtPTP as the target for neuroprotection in LHON 
 
In a scenario where the reuptake of calcium back to the endoplasmic stores is 
inhibited by TG, mitochondria are expected to play the role of calcium buffering organelles 
that take up and thereby increase the matrix calcium concentration (Ichas and Mazat, 1998; 
Korge and Weiss, 1999). This leads to a stimulation of the respiratory chain and increases 
free radical generation (especially in the case of respiratory chain mutations) and eventually 
results in the opening of the mtPTP (Takeyama et al., 1993). Opening of the mtPTP leads to 
the release of mitochondrial calcium back into the cytosol. The normalization of calcium 
dynamics by mtPTP inhibition has previously been discussed (Bernardi and Petronilli, 
1996, Rizzuto et al., 2000, Andrabi et al., 2004). In the performed live cell calcium imaging 
experiments minocycline had similar effects on cellular calcium dynamics as CsA in 
TG/AcCh-induced deregulation of calcium in the cybrid cells. There are previous reports 
showing that minocycline is able, like CsA, to inhibit the permeability transition in isolated 
brain and liver mitochondria (Zhu et al., 2002; Fernandez-Gomez et al., 2005a; Fuks et al., 
2005). As seen in calcium imaging experiments the restoration of calcium dynamics 
suggests accordingly that in LHON cybrid cells minocycline is able to inhibit calcium 
overload-induced mtPTP formation significantly. In the parent cell line, applying the same 
set of experiments, neither minocycline nor CsA show any deviation of end calcium 
dynamics from TG per se group as observed in the LHON cybrid cells, which indicated that 
the mtPTP was not activated upon TG perfusion in the parental cell line. The increasing 
fluorescence ratio with buffer perfusion observed both in cybrid cells and the parental cell 
line is most likely due to leakage of the dye from the cell.  
 
4.1.2 Mitochondrial membrane potential is conserved by minocycline 
 
Mitochondrial ΔΨm is the driving force of ATP production and the calcium buffering 
capacity of the mitochondria. The calcium is taken up by the mitochondria through a 
selective calcium uniporter and is accumulated at concentrations 100 times higher than in 
the cytosol. TMRM, a positively charged red fluorescent dye, is taken up by the 
mitochondria due to their negative ΔΨm (Scaduto and Grotyohann, 1999). Upon opening of 
the mtPTP the ΔΨm of mitochondria is lost (Blattner et al., 2001) and the dye is not taken 
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up. Mitotracker green, however, is taken up by mitochondria irrespective of their ΔΨm. The 
overlap of the two fluorescence images gives an idea of the proportion of cells that have 
intact mitochondrial ΔΨm. TG has been earlier shown to decrease the mitochondrial ΔΨm 
(Yamazaki et al., 2006). The presented data also suggest that TG decreases the number of 
cells with preserved mitochondrial ΔΨm and that in cybrid cells minocycline can conserve 
this loss of ΔΨm. The involvement of mtPTP in this set of experiments is confirmed by the 
conservation of mitochondrial ΔΨm by CsA. These results are consistent with those 
obtained with live cell calcium imaging experiments and suggest that minocycline could act 
as anti-apoptotic agent by inhibiting the mtPTP. In NT2 cells even though the loss of 
mitochondrial ΔΨm was significant in the TG treated group, minocycline and CsA did not 
significantly reverse the dissipation of ΔΨm, indicating that the mitochondrial ΔΨm loss in 
the NT2 cells was CsA insensitive and therefore not due to mtPTP. The MDR inhibiting 
activity of CsA which might indicate false positives is eliminated by the use of its congener 
CsH, which possesses similar MDR inhibiting activity without mtPTP blocking effect, in 
similar set of experiments. If we consider the result obtained with CsH on TMRM uptake 
experiment as an indicative of similar MDR inhibiting activity of CsA and nullify the effect 
of former from that of latter, one could expect that the effect of CsA and minocycline on 
TMRM uptake would be comparable.  
 
4.1.3 LHON disorder could benefit from antioxidant property of 
minocycline  
 
As mentioned in the introduction, the symptoms of LHON disorder are influenced by 
age, gender and environmental factors which are commonly explained by a lacking capacity 
of the cell to encounter oxidative stress. With age the declining endogenous antioxidant 
pool and antioxidant enzyme activity of the cell can exaggerate the oxidative stress (Wei 
and Lee, 2002; Maher, 2005). In females the appearance of the LHON symptoms at a later 
age than in males can accordingly be explained by the presence of higher levels of 
oestrogen, an up-regulator of antioxidant genes (Vina et al., 2005). Smoking and alcohol 
consumption aggravate the oxidative load of the cell and consequently increase the relative 
risk of developing symptoms of LHON disorder (Tsao et al., 1999, Carelli et al., 2004a). 
The upregulation of cellular antioxidant systems has been shown to be a promising target to 
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rescue cells with LHON mutation (Qi et al., 2007a). In our study DFF imaging 
demonstrated a decrease in baseline fluorescence values with all except the lowest 
concentration of minocycline treatments similar to the decrease observed in vitamin c 
treatment. Additionally, the decrease was not observed with CsA as it lacks anti-oxidant 
properties. Induction of oxidative stress with H2O2 was dose dependently alleviated by 
minocycline as well as with 100µM vitamin C, but the same was not true for CsA treatment. 
These results support previous reports of antioxidant properties of minocycline (Kraus et al., 
2005), which may contribute to its protective effect. Minocycline treatments reduced the 
basal fluorescent values and consequently the oxidative stress in LHON cybrids to a level 
where they are comparable to that observed in NT2 cells. The present findings suggest that 
minocycline, even at doses lower than 100 µM, can relieve the LHON cybrid cells of their 
inherent oxidative stress. The increase in cell viability seen in MTT assay was therefore not 
entirely dependent on the antioxidant property of the drug, but was also a consequence of 
mtPTP pore inhibition similar to that revealed in the performed experiments with CsA 
treatment, and in accordance with previous reports supporting minocycline to be an 
inhibitor of mtPTP (Zhu et al., 2002; Fernandez-Gomez et al., 2005a; Fuks et al., 2005).  
Figure 25: Possible targets of minocycline in preventing cell death of LHON cybrids. 
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4.2 Therapeutic strategies in LHON and minocycline 
 
Advances in our understanding of the molecular genetic basis of LHON have 
revolutionized our ability to diagnose and prognosticate this disease. There are currently no 
clinical management protocols and specific therapeutic guidance for LHON and it presents 
formidable challenges to the design and conduction of clinical trials. The acutely 
symptomatic LHON patient with monocular vision loss provides a unique clinical situation 
of a limited duration in which to test an agent during a critical therapeutic window. 
Advances in neuroprotection, apoptosis, and neurodegenerative diseases may provide 
important clues for potential therapeutic agents for LHON. Antioxidants and agents that 
interfere with the critical steps of mitochondrial-dependent, oxidative stress-induced 
apoptosis are candidates for future LHON therapy (Johns and Colby 2002). A variety of 
neuroprotective agents, under active investigation in other diseases, may be useful in LHON 
therapy. Effective pharmacotherapy will complement the current management approach that 
has changed little in the 130 years since LHON was originally described. Recently a 
possibility of investigation of drugs in a mouse model of LHON has emerged which might 
accelerate drug development (Qi et al., 2007b). Therapies, targeting the function of the 
respiratory chain (ETC) and targeting ETC born ROS species are currently under 
discussion. At present, a clinical trial with the anti-oxidative ubiquinone-analogue 
idebenone is being performed in Great Britain and Germany, supervised by the Newcastle 
mitochondrial genetics group (Newcastle upon Tyne). In this trial, patients who developed 
recently LHON in one eye are experimentally treated with idebenone to rescue the second 
eye (second eye approach). Since individuals carrying a LHON mutation must not 
necessarily develop the disease, the risks of a general treatment of mutation carriers are 
considered to be too high. It is well known, especially from investigations of the large 
Brazilian pedigree (Sadun, et al., 2002; Sadun, et al., 2003; Sadun, et al., 2004), that even 
homoplasmic carriers must not necessarily develop the disease and that some additional risk 
factors, such as smoking exist. Precise ophthalmologic investigations may help to identify 
carriers prone to develop LHON in the near future. If some more data would have been 
collected in LHON models, the risk of applying the well established drug minocycline in 
such a “second eye approach” in humans may become tolerable.  
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Although 2.0 – 3.0 µM CsA reversed partially the TG induced toxicity the long term 
usage of such concentrations in vivo is certainly not applicable to human LHON disease. 
Blood concentrations in the target levels of 180 - 300 ng/ml (0.15 - 0.25 µM), occurring if 
CsA is used as an immunosuppressive drug, are known to cause several side effects in a 
considerable percentage of patients. Besides increased arterial blood pressure, also several 
neurological complications have been described, such as tremor (in up to 40 % of cases), 
mild encephalophathy (in up to 30 %), seizures (1.5 – 6 %), dysarthria, cerebellar ataxia and 
peripheral neuropathy (Gijtenbeek, et al., 1999). Thus in vivo the toxic side effects seem to 
exceed the desired protective effects, measurable in the cybrid system. In contrast 
minocycline has a high safety profile and possess antioxidant properties, as demonstrated by 
the live cell DFF-imaging the LHON cybrid model. On the other hand, the achieved serum 
peak concentrations of minocycline in humans is about 5 - 6 µg/ml (around 12 µM) after 
200 mg intravenous application. It remains uncertain, whether sufficient tissue 
concentrations can be reached. In case of LHON, the blood brain barrier has to be taken into 
account, which probably allows only a fraction of this concentration to reach the retinal 
ganglion cell layer and the optic nerve. However, recently it has been shown that in blood-
brain barrier transport studies in mice after intra-peritoneal injection of 90 mg minocycline / 
kg and determined plasma concentrations of minocycline in the range of 40 – 60 µg/ml 
(around 80 – 120 µM) and corresponding brain/plasma ratio around 0,08 (corresponding to 
about 6 – 9 µM uptake into the CNS) (Milane, 2007). Similar results (2.8 µg/ml; approx. 
6 µM) have been reported for cerebrospinal fluid from rats (Fagan, et al., 2004). After oral 
administration (120 mg/kg) in mice after 8 hours midbrain minocycline levels of 0.32 µg/g 
were described (Du, et al., 2001). To the present knowledge, no data are currently available 
concerning minocycline concentrations in retina or optic nerve. Theoretically, a direct 
application of minocycline into the vitreous maybe taken into account, as it is already 
performed nowadays with e.g. anti-inflammatory drugs in some cases. However, this 
possibility seems to be rather unrealistic, since even the acute phase of LHON must be 
viewed only as a manifestation of a basically chronic retinal disease, which would require a 
long term neuroprotective medication. The drug can be delivered efficiently only via oral or 
other systemic routes. The surprisingly small window of effective concentrations found in 
current experiments (100 –125 µM) is in contrast to the broader therapeutic window 
observed during antibiotic therapy in vivo. This difference may just reflect the ineffective 
uptake of minocycline by the cybrid cells or possibly a higher rate of metabolic breakdown 
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in which case the effective in vivo concentrations can predictably be lower. However, the 
higher tolerability and effectiveness exhibited by minocycline in the cybrid cells will most 
likely not be manifested in higher animal studies. Further studies are necessary to determine 
the local concentration needed in the retina and around the optic nerve and to find out a 
relevant minocycline concentration in relation to a route of drug administration to attain 
neuroprotection in-vivo. On the way to that point, it would be highly interesting, to test the 
potential benefit of minocycline in a mouse LHON model, which was recently developed by 
the group of John Guy who showed for the first time that a transfection of mouse retina with 
viral vectors, allotopically expressing a mutant human ND4 subunit did develop elevated 
ROS production, optical nerve head swelling, apoptosis and progressive loss of retinal 
ganglion cells (Qi et al., 2007b). These effects did not occur in mice transfected with wild 
type human ND4. This was the first true genetic animal model of LHON, which should be 
suitable in vivo pharmaceutical drug testing model, prior to a “second eye approach” in 
humans. 
 
The lack of sufficient uptake into the CNS and a probably narrow range of useful 
concentrations, as shown in this study to be higher than that which is clinically achievable 
in the retinal ganglion cell layer, might however, limit the usefulness of minocycline in 
LHON therapy. Also the controversially discussed effects of minocycline in various models 
of neurodegeneration and neuroprotection restrict a conclusive assumption of its usefulness. 
Furthermore, it is difficult to directly correlate the protective effects of minocycline in our 
relatively simple model of LHON to the RGC layer, where we cannot yet completely 
comprehend the complexities of the in-vivo environment and the nature of possible 
interactions of the ganglions with their surroundings. Nevertheless, we conclude that the 
protective effect shown by minocycline in the present experiments on LHON cybrid cells, 
along with its well-established clinical use, makes it an interesting drug for further 
investigations in therapy of LHON disease, possibly as a next step, in a mutant ND4 
transgenic mouse like that described by Qi et al. (Qi et al., 2007b). 
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5. SUMMARY 
 
Leber’s Hereditary Optic Neuropathy (LHON) is a retinal ganglionic 
neurodegenerative disorder caused by a maternally inherited mitochondrial DNA point 
mutation. The dysfunction of complex I of the respiratory chain, affected by the mutation, 
results in an increased production of reactive oxygen species and a decreased synthesis of 
ATP. This biochemical scenario can lead to an imbalance in the production and demand of 
energy required for cell survival. In such a state the cell may die by apoptosis, which in 
LHON disorder is most prominently apparent as optic nerve degeneration. Cybrid cells are 
the most frequently used model for this disease as the optic nerve of a LHON patient is not 
accessible until the death of the patient and by which time the degeneration is to its full 
extent. 
 
The aim of this study was the establishment of a cell-mediated LHON-model for 
evaluation of antioxidants and neuroprotective drugs and to discover the involvement of the 
mitochondrial permeability transition pore (mtPTP) in development of the disorder. Using 
cybrid cells harbouring the mitochondrial 11778 LHON point mutation, the efficacy of the 
promising neuroprotective tetracycline derivative minocycline was investigated. The drug 
increased the cell viability of LHON cybrids in the MTT assay after addition of the 
apoptotic stimulus, thapsigargin (TG). In contrast, this pattern of protection was not evident 
in the parental control cell line (NT2). A comparable protection to minocycline was 
observed by treatment with cyclosporine A (CsA), a well known blocker of the mtPTP. 
Furthermore, a general caspase inhibitor (z-VAD-FMK) did not prevent the thapsigargin-
induced cell death in either of the cell lines. Whereas, staining of the nuclei with DAPI 
showed nuclear condensation and apoptotic morphology of the cell. In support of this, 
immunocytochemistry revealed the release of the apoptosis-inducing factor (AIF) from the 
mitochondria and translocation to the nucleus, suggesting an mtPTP-induced caspase 
independent apoptosis. Ratiometric Ca
2+
 imaging reveals that acetylcholine/TG triggered 
elevation of the cytosolic calcium concentration is alleviated by both minocycline and CsA, 
also suggesting an involvement of permeability transition. In addition the mitochondrial 
membrane potential (ΔΨm) of LHON cybrid cells, as evaluated by the uptake of TMRM, 
was significantly conserved with both minocycline and CsA treatments. Western blots 
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showed a decrease in the ratio of active-caspase-3 to procaspase-3 proteins in the 
minocycline and CsA treated groups of cybrid cells after TG-induced cell death, which 
suggests the regulation of downstream apoptotic events. This is in contradiction to the 
obtained results in the MTT assay using z-VAD-FMK, which indicates that the TG-
triggered cell death is a non-caspase-dependent process. The release of pro-apoptotic factors 
(e.g. AIF) from the mitochondria is the proposed mechanism of cell death. But parallel 
pathways, causing activation of caspases, are also possibly active. Blockade of the mtPTP 
opening by CsA and minocycline prevents death of the LHON cybrids. Additionally, 
minocycline dose dependently decreased the oxidative stress in LHON cells, supporting the 
effective anti-oxidant property of this tetracycline. 
 
In conclusion, the opening of the mtPTP is involved in the onset of LHON and 
minocycline provides beneficial effects, beside its antioxidant property, through inhibition 
of mtPTP. Further investigation into the effect of minocycline, possibly in an in vivo model 
of the disease, such as a LHON ND4 mutant mouse, would be necessary to prove its 
protective mechanisms on the retinal ganglionic cell layer and the optic nerve. 
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6. ZUSAMMENFASSUNG 
 
Die Lebersche hereditäre Optikusneuropathie (LHON) ist eine neurodegenerative 
Erkrankung des Sehnervs, die von der Mutter weitervererbt und durch Punktmutationen der 
mitochondrialen DNA verursacht wird. Die Fehlfunktion des betroffenen Komplexes I der 
Atmungskette führt zu einer erhöhten Produktion reaktiver Sauerstoffspezies und einer 
Abnahme der ATP-Synthese. Diese Situation kann ein Ungleichgewicht zwischen der 
Herstellung und der zum Überleben der Zelle benötigten Menge an Energie zu Folge haben. 
Unter solchen Bedingungen könnte die Zelle durch Apoptose sterben, was bei LHON als 
Degeneration des Sehnervs offenkundig wird. Cybrid-Zellen sind das am häufigsten 
benutzte Modell für diese Erkrankung, da der Sehnerv von LHON-Patienten erst nach dem 
Tod zugänglich und zu diesem Zeitpunkt die Degeneration meist in vollem Umfang 
ausgeprägt ist. 
 
Ziel der Untersuchungen war die Etablierung eines zellulären Schädigungsmodells für 
LHON, um einerseits die Wirkung von Antioxidantien und Neuroprotektiva zu beurteilen 
und andererseits die Beteiligung der mitochondrialen Permeabilitätstransitionspore (mtPTP) 
bei der Ausprägung der Erkrankung zu untersuchen. Unter Verwendung von Cybrid-Zellen 
mit einer mitochondrialen LHON-Mutation an Position 11778 wurde die Wirksamkeit des 
vielversprechenden neuroprotektiven Tetracyclin-Derivats Minocyclin untersucht. Das 
Medikament erhöhte die Lebensfähigkeit der LHON-Cybrid-Zellen in MTT-Analysen nach 
Applikation des Apoptose auslösenden Stimulus Thapsigargin (TG). In der als Kontrolle 
verwendeten Ausgangszelllinie NT2 war im Gegensatz dazu diese Art des Schutzes nicht 
nachweisbar. Eine zu Minocyclin vergleichbare Protektion wurde nach Behandlung mit 
Cyclosporin A (CsA), einem bekannten Blocker der mtPTP, beobachtet. Der Einsatz eines 
allgemeinen Caspase-Inhibitors (z-VAD-FMK) konnte den durch TG induzierten Zelltod in 
keiner der beiden Zelllinien verhindern. Hingegen waren die Kondensation des Chromatins, 
detektiert mittels DAPI-Färbung, und die apoptotische Morphologie der Zellen erkennbar. 
Weiterhin konnte immunhistochemisch die Freisetzung des Apoptose induzierenden Faktors 
(AIF) aus den Mitochondrien und dessen Translokation in den Zellkern nachgewiesen 
werden, was auf mtPTP induzierte und Caspasen unabhängige Apoptose hinweist. 
Ratiometrische Messungen des intrazellulären Ca
2+
 ergaben, dass die durch 
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Acetylcholin/TG ausgelöste Erhöhung der cytosolischen Ca
2+
-Konzentration durch 
Minocyclin und CsA abgeschwächt wird, was ebenfalls für eine Beteiligung der mtPTP 
spricht. Zusätzlich war das mitochondriale Membranpotential (ΔΨm) der LHON-Cybrid-
Zellen, ermittelt durch die Aufnahme von TMRM, signifikant besser konserviert nach einer 
Behandlung mit Minocycline und CsA. Western blot-Analysen zeigten eine Abnahme des 
Verhältnisses von aktivierter Caspase 3 zu Procaspase 3 in den mit Minocyclin und CsA 
behandelten Gruppen nach TG-induziertem Zelltod, was auf die Regulation 
nachgeschalteter apoptotischer Ereignisse hinweist. Dies steht jedoch im Widerspruch zu 
den unter Verwendung von z-VAD-FMK erhaltenen Ergebnissen in den MTT-
Experimenten, welche auf einen Caspase unabhängigen Prozess hindeuten. Die Abgabe pro-
apoptotischer Faktoren (z.B. AIF) von Mitochondrien und die Aktivierung von Caspasen 
stellen die Ursache für den beobachteten Zelltod dar. Eine Blockade der Öffnung der mtPTP 
durch CsA und Minocyclin kann den Untergang der LHON-Cybride verhindern. Zusätzlich 
verringerte Minocyclin konzentrationsabhängig den oxidativen Stress in LHON-Zellen, was 
die guten antioxidativen Eigenschaften dieses Tetracyclins bestätigt. 
 
Schlussfolgernd ist festzustellen, dass ein Öffnen der mtPTP an der Pathogenesse der 
LHON beteiligt ist und Minocyclin, neben seiner Eigenschaft als Antioxidant, vorteilhafte 
Effekte durch die Hemmung der mtPTP besitzt. Weitere Untersuchungen zu den 
Auswirkungen von Minocyclin in in vivo Modellen dieser Erkrankung (z.B. an Mäusen mit 
ND4-Mutation) sind erforderlich, um den schützenden Mechanismus an retinalen 
Ganglienzellen und Sehnerv zu beweisen. 
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7. ABBREVIATIONS 
 
ΔΨm      mitochondrial membrane potential 
aC3/pC3      active-caspase 3/pro-caspase 3 
AIF      apoptosis inducing factor 
ALS      amyotrophic lateral sclerosis 
ANT      adenosine nucleoside translocase 
ATP      adenosine triphosphate 
BCA      bicinchoninic acid 
BSA      bovine serum albumin 
CsA       cyclosporin A 
CsH      cyclosporin H 
CoQ      coenzyme Q 
Cyc      cytochrome c 
CyP D      cyclophilin D 
DFF       difluorofluorescein 
DIABLO direct inhibitor of apoptosis protein binding 
protein with low pI 
DMEM     Dulbecco modified Eagle's medium 
EAAT      excitatory amino acid transporter 
ER      Endoplasmic reticulum 
ETC      electron transport chain 
FAD      flavin adenine dinucleotide 
FCS      fetal Calf Serum 
H2O2      hydrogen peroxide  
LHON      Leber’s hereditary optic neuropathy 
MDR      multidrug resistance pump 
mtPTP      mitochondrial permeability transition pore 
mtDNA      mitochondrial DNA 
MTT       methylthiazolyldiphenyl-tetrazolium bromide 
NADP      nicotinamide adenine dinucleotide phosphate 
OMM      outer mitochondrial membrane 
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PBS      phosphate buffer saline 
PDL      poly-D-lysine 
PT      permeability transition 
rcf      relative centrifugal force 
RGC      retinal ganglionic cells 
ROI      region of interest 
ROS       reactive oxygen species 
SMAC second mitochondria-derived activator of 
caspases 
SR      sarcoplasmic reticulum 
TG       thapsigargin 
TMRM      tetramethyl rhodamine methyl ester 
UP      calcium uniporter 
VDAC      voltage dependent anionic channel 
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